n-Lorem Foundation

Founded in 2020, the n-Lorem Foundation is pioneering an entirely new model of drug discovery and development for patients who are entirely unserved: the nano-rare. We define nano-rare patients as those individuals who have a single genetic mutation expressed in fewer than 30 people worldwide. 

With a seasoned leadership team and strategic partnerships, the n-Lorem Foundation provides the framework, funds, and access for nano-rare patients who are amenable to our technology to receive experimental antisense oligonucleotides (ASOs) for free, for life.

We believe a non-profit approach is the only way to treat nano-rare patients, as any commercial scale approach would require that they be charged millions of dollars. We believe our industry is obligated to do better than that, so armed with ASO technology, we can and we are.